Merck immunotherapy drug shows promise against lymphoma -study

Dec 6 (Reuters) - Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting.